Table 2.
Pathological and clinical characteristics of breast cancer samples in relation to metastasis-free survival (MFS).
Non-IBC |
IBC |
|||||
---|---|---|---|---|---|---|
Number of patients (%) | Number with metastases (%) | MFS p-value a | Number of patients (%) | Number with metastases (%) | MFS p-value a | |
Total | 182 (100) | 65 (35.7) | 135 (100) | 70 (51.9) | ||
Age | ||||||
≤50 | 37 (20.3) | 10 (27.0) | 0.15 (NS) | 58 (43.0) | 29 (38.6) | 0.54 (NS) |
>50 | 145 (79.7) | 55 (37.9) | 77 (57.0) | 41 (41.6) | ||
SBR histological gradeb | ||||||
I | 20 (11.2) | 2 (10.0) | 0.035c | 2 (1.5) | 0 (0.0) | |
II | 99 (55.3) | 40 (40.4) | 48 (36.6) | 27 (56.3) | 0.44 (NS) d | |
III | 60 (33.5) | 23 (38.3) | 81 (61.8) | 41 (50.6) | ||
Stage | ||||||
I | 16 (8.8) | 3 (18.8) | 0.00021 | 0 (0.0) | 0 (0.0) | – |
IIA | 55 (30.2) | 13 (23.6) | 0 (0.0) | 0 (0.0) | ||
IIB | 67 (36.8) | 24 (35.8) | 0 (0.0) | 0 (0.0) | ||
IIIA | 35 (19.2) | 18 (51.4) | 0 (0.0) | 0 (0.0) | ||
IIIB | 9 (4.9) | 7 (77.8) | 135 (1 0 0) | 70 (51.9) | ||
ER status | ||||||
Negative | 49 (26.9) | 13 (26.5) | 0.17 (NS) | 76 (58.5) | 35 (46.1) | 0.49 (NS) e |
Positive | 133 (73.1) | 52 (39.1) | 54 (41.5) | 32 (59.3) | ||
PR status | ||||||
Negative | 77 (42.3) | 26 (33.8) | 0.94 (NS) | 95 (73.6) | 49 (51.6) | 0.41 (NS) f |
Positive | 105 (57.7) | 39 (37.1) | 34 (26.4) | 17 (50.0) | ||
ERBB2 status | ||||||
Negative | 149 (81.9) | 53 (35.6) | 0.94 (NS) | 88 (67.7) | 50 (56.8) | 0.042e |
Positive | 33 (18.1) | 12 (36.4) | 42 (32.3) | 17 (73.8) | ||
Molecular subtypes | ||||||
HR- ERBB2- | 28 (15.4) | 8 (28.6) | 0.84 (NS) | 39 (30.5) | 20 (51.3) | 0.19 (NS) h |
HR- ERBB2+ | 17 (9.3) | 5 (29.4) | 33 (25.8) | 12 (36.4) | ||
HR + ERBB2- | 121 (66.5) | 45 (37.2) | 47 (36.7) | 29 (61.7) | ||
HR + ERBB2+ | 16 (8.8) | 7 (43.8) | 9 (7.0) | 5 (55.6) |
Abbreviations: ER: estrogen receptor alpha; PR: progesterone receptor; ERBB2: human epidermal growth factor receptor 2; HR: hormone receptor. Bold values are statistically significant (p-value < 0.05).
a Log-rank Test; b Scarff-Bloom-Richardson classification; c Information available for 179 patients; d Information available for 131 patients; e Information available for 130 patients; f Information available for 129 patients; h Information available for 128 patients.